Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-085 plus Vemurafenib in BRAF V600 Mutant Advanced Solid Tumor
NCT03781219Phase 1Unknown
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tunlametinib in solid tumor, sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoint: Number of Adverse Events up to 12 months. Status: unknown.
02
Drugs
tunlametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03781219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781219.